[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study

Gagel, Bernd; Reinartz, Patrick; Demirel, Cengiz Bekir; Kaiser, Hartmut; Zimny, M.; Piroth, Marc D.; Pinkawa, Michael; Stanzel, S.; Asadpour, Branka; Hamacher, Kurt; Coenen, Heinz H.; Buell, U.; Eble, Michael J.

doi:10.1186/1471-2407-6-51

Cited by 101 publications

(75 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bentzen et al [195] , Rasey et al [196] , Bentzen et al [197] , Troost et al [198] Bentzen et al [125] , Gagel et al [126] , Bruehlmeier et al [199] , Lawrentschuk et al [200] , O'Donoghue et al [72] , Piert et al [166] , Sørensen et al [201] , Gagel et al [202] , Carlin et al [203] , Chang et al [204] , Mortensen et al [127] Hatano et al [205] , Huang et al [206] , Huang et al [207] , Oehler et al [208] , Cho et al [209] , Troost et al [210] , Matsumoto et al [136] , Troost et al [198] , Dubois et al [211] Dubois et al [211] , Cherk et al [212] , Riesterer et al [213] , Lehmann et al [214] , Chen et al [215] , Campanile et al [216] , Cheng et al [217] , Sato et al [218] , Norikane et al [219] Cherk et al [212] , Eschmann et al [77] , Gagel et al [82] , Koh et al [87] , Rasey et al [220] , Vera et al…”

Section: F]fmisomentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

Core tip:This review provides an overview of the current applications of positron emission tomography for hypoxia and perfusion imaging in lung cancer. Available PET tracers are discussed and the benefits of combined hypoxia and perfusion PET imaging are clarified. Hypoxia imaging could aid in selecting patients for hypoxia-specific treatment strategies. To achieve this, consensus about the optimal imaging protocol and quantification method is essential. Large clinical trials are needed to confirm the value of hypoxia imaging for improving patient care.Verwer EE, Boellaard R, van der Veldt AAM. Positron emission tomography to assess hypoxia and perfusion in lung cancer.

show abstract

Section: F]fmisomentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

show abstract

“…Another approach takes advantage of the nearuniversal increase in nonmitochondrial ATP synthesis observed in oxygen deprived cells (i.e., the Pasteur effect), and may include assessment of glycolytic flux [e.g., with [ 18 F]-fluorodeoxyglucose positron emission tomography ( 18 F-FDG-PET)] or molecular manifestations of the Pasteur effect (e.g., expression of Glut-1 and other HIF-1 targets), but results have been mixed. [7][8][9][10][11][12][13][14][15][16][17][18] The main purpose of this study was to identify, if possible, a common underlying biological variable that may explain the reported inconsistency. Accordingly, we hypothesized that the specificity/usefulness of biochemical or molecular adjustments, that shifts metabolism towards anaerobiosis, as surrogate markers of hypoxia, is inversely correlated with the tumors relative reliance on aerobic glycolytic ATP production (i.e., the magnitude of the Warburg effect).…”

mentioning

confidence: 99%

Aerobic glycolysis in cancers: Implications for the usability of oxygen‐responsive genes and fluorodeoxyglucose‐PET as markers of tissue hypoxia

Busk

Horsman

Kristjansen

et al. 2008

Intl Journal of Cancer

108

View full text Add to dashboard Cite

The hypoxia-responsiveness of the glycolytic machinery may allow pretreatment identification of hypoxic tumors from HIF-1 targets (e.g., Glut-1) or [18F]-fluorodeoxyglucose positron emission tomography but results have been mixed. We hypothesized that this discrepancy is an inevitable consequence of elevated aerobic glycolysis in tumors (Warburg effect) as energetics in predominantly glycolytic cells is little affected by hypoxia. Accordingly, we characterized glycolytic and mitochondrial ATP generation in normoxic and anoxic cell lines. Measurements demonstrated that most cancer cells rely largely on aerobic glycolysis as it accounts for 56-63% of their ATP budget, but in the cervical carcinoma SiHa, ATP synthesis was mainly mitochondrial. Moreover, the stimulatory effect of anoxia on glycolytic flux was inversely correlated to the relative reliance on aerobic glycolysis. Next, tumor cells representing a Warburg or a nonglycolytic phenotype were grown in mice and spatial patterns of hypoxia (pimonidazolestained), Glut-1 expression and 18 F-FDG uptake were analysed on sectioned tumors. Only in SiHa tumors did foci of elevated glucose metabolism consistently colocalize with regions of hypoxia and elevated Glut-1 expression. In contrast, spatial patterns of Glut-1 and pimonidazole staining correlated reasonably well in all tumors. In conclusion, Glut-1's value as a hypoxia marker is not severely restricted by aerobic glycolysis. In contrast, the specificity of 18 F-FDG uptake and Glut-1 expression as markers of regional hypoxia and glucose metabolism, respectively, scales inversely with the intensity of the Warburg effect. This linkage suggests that multi-tracer imaging combining FDG and hypoxia-specific markers may provide therapeutically relevant information on tumor energetic phenotypes. ' 2008 Wiley-Liss, Inc.Key words: hypoxia; Warburg; Pasteur; fluorodeoxyglucose; Glut-1 German biologist Otto Warburg 1 changed our understanding of tumor energy metabolism, by demonstrating that cancer cells deviate from their nontransformed counterparts by a vigorous formation of lactate even in the presence of oxygen (i.e., aerobic glycolysis). Mitochondrial defects are widespread in cancers and Warburg rationally hypothesized that impaired respiratory capacity leads to a compensatory increase in glycolysis. However, the cause and effect relationship between the oxidative phosphorylation (OXPHOS) and aerobic glycolysis is unclear, as at least some cancer cell lines are able to increase oxygen consumption rate (OCR) when glycolysis is inhibited or when treated with mitochondrial uncouplers. 2,3 Cancer cell energy metabolism has received renewed interest recently, when some common oncogenic mutations have been directly linked to the glycolytic phenotype, 4,5 but tumor hypoxia is common, and the imposed ATP deficit could be an important trigger of high glucose consumption in vivo (Pasteur effect).Tumor hypoxia, in particular in squamous cell carcinomas (SCCs), adversely affects prognosis by enhancing resistance to radio-and ch...

show abstract

“…[ . This tracer has been evaluated extensively for the detection of tumor hypoxia both preclinically, using different animal models 277,278 , and clinically, for different cancer types 279,280 . Our group was the first to validate the potential of this PET technique using a nitroimidazole related histopathology assay 281 , which was confirmed by others 282 .…”

Section: Imaging Acute and Chronic Tumor Hypoxiamentioning

confidence: 99%